Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE - PubMed (original) (raw)
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
C Bombardier et al. Arthritis Rheum. 1992 Jun.
Abstract
Objective: To standardize outcome measures in systemic lupus erythematosus (SLE). Three indices were identified which could adequately describe outcome (disease activity, damage from disease, and health status); we describe here the development of the Disease Activity Index.
Methods: Twenty-four variables were identified as important factors in a disease activity index. These were used to generate 574 patient profiles, which were rated on a disease activity scale of 0-10 by 14 rheumatologists. A second rating of 10 of the profiles yielded scores that were not significantly different from the first, indicating that experienced clinicians can reliably make global estimates of disease activity. Multiple regression models were used to estimate the relative importance of the 24 clinical variables in the physicians' global rating of disease activity. These were estimated on a "training set" of 75% of physicians' ratings, and then validated on a "testing set," consisting of the remaining 25% of physicians' ratings.
Results: The explanatory power of the models in the training set was high (R2 = 0.93). The models' regression coefficients for the organ systems were simplified for easier use in clinical practice. This generated a "weighted" index of 9 organ systems for disease activity in SLE, the SLEDAI, as follows: 8 for central nervous system and vascular, 4 for renal and musculoskeletal, 2 for serosal, dermal, immunologic, and 1 for constitutional and hematologic. The maximum theoretical score is 105, but in practice, few patients have scores greater than 45. The SLEDAI predicted well the physicians' ratings in the testing set (Pearson's correlation coefficients = 0.64-0.79).
Conclusion: The SLEDAI is a validated model of experienced clinicians' global assessments of disease activity in lupus. It represents the consensus of a group of experts in the field of lupus research.
Similar articles
- Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
Ward MM, Marx AS, Barry NN. Ward MM, et al. J Rheumatol. 2000 Mar;27(3):664-70. J Rheumatol. 2000. PMID: 10743805 - Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT).
Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S, Marchesoni A, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Kovacs A, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Dratwianka B, Kiss E, Cikes N, Anic B, Schneider M, Fischer R, Bombardieri S, Mosca M, Graninger W, Smolen JS; Study group on incomplete SLE and SLE with disease duration longer than 10 years. Swaak AJ, et al. Rheumatology (Oxford). 2001 Jan;40(1):89-94. doi: 10.1093/rheumatology/40.1.89. Rheumatology (Oxford). 2001. PMID: 11157147 - Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.
Griffiths B, Mosca M, Gordon C. Griffiths B, et al. Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708. doi: 10.1016/j.berh.2005.03.010. Best Pract Res Clin Rheumatol. 2005. PMID: 16150398 Review. - Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón I, Tani C, Jolly M, Huang A, Mosca M. Castrejón I, et al. Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-85-95. Epub 2014 Oct 30. Clin Exp Rheumatol. 2014. PMID: 25365095 Review.
Cited by
- Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus.
Jovanović V, Abdul Aziz N, Lim YT, Ng Ai Poh A, Jin Hui Chan S, Ho Xin Pei E, Lew FC, Shui G, Jenner AM, Bowen L, McKinney EF, Lyons PA, Kemeny MD, Smith KG, Wenk MR, Macary PA. Jovanović V, et al. PLoS One. 2013;8(2):e55639. doi: 10.1371/journal.pone.0055639. Epub 2013 Feb 7. PLoS One. 2013. PMID: 23409013 Free PMC article. - Absolute quantification and characterization of oxylipins in lupus nephritis and systemic lupus erythematosus.
He J, Ma C, Tang D, Zhong S, Yuan X, Zheng F, Zeng Z, Chen Y, Liu D, Hong X, Dai W, Yin L, Dai Y. He J, et al. Front Immunol. 2022 Oct 6;13:964901. doi: 10.3389/fimmu.2022.964901. eCollection 2022. Front Immunol. 2022. PMID: 36275708 Free PMC article. - Lupus enteritis: from clinical findings to therapeutic management.
Janssens P, Arnaud L, Galicier L, Mathian A, Hie M, Sene D, Haroche J, Veyssier-Belot C, Huynh-Charlier I, Grenier PA, Piette JC, Amoura Z. Janssens P, et al. Orphanet J Rare Dis. 2013 May 3;8:67. doi: 10.1186/1750-1172-8-67. Orphanet J Rare Dis. 2013. PMID: 23642042 Free PMC article. Review. - (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients.
Malviya G, Anzola KL, Podestà E, Laganà B, Del Mastro C, Dierckx RA, Scopinaro F, Signore A. Malviya G, et al. Mol Imaging Biol. 2012 Oct;14(5):637-46. doi: 10.1007/s11307-011-0527-x. Mol Imaging Biol. 2012. PMID: 22127469 Free PMC article. Clinical Trial. - Overexpression of X-linked genes in T cells from women with lupus.
Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune WJ, Somers E, Gonzalez-Rivera T; Michigan Lupus Cohort; Strickland F, Richardson B. Hewagama A, et al. J Autoimmun. 2013 Mar;41:60-71. doi: 10.1016/j.jaut.2012.12.006. Epub 2013 Feb 19. J Autoimmun. 2013. PMID: 23434382 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical